The U.S. Food and Drug Administration took the uncommon step of publishing photographs showing dilapidated buildings at a drug manufacturing facility in Daman, India, as part of a formal warning letter issued last week. The images reveal deteriorating structural conditions at the site.
This represents a notable departure from the FDA's typical approach to facility violations, as the agency rarely includes visual documentation in its public warning letters. The move suggests heightened concerns about manufacturing standards at international drug production sites.